ENDPOINTS NEWS2h
No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis
SAN AN­TO­NIO — No­vo Nordisk’s wild­ly pop­u­lar an­ti-obe­si­ty drug We­govy helped heart dis­ease pa­tients end up in the ...
ENDPOINTS NEWS5h
Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates
CinFina Pharma, a subsidiary of the hub-and-spoke biotech CinRx, shared early-stage data for two of its Janssen-licensed ...